Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 14/20 | 0.68 |
| ▸ | PRSS1 | P07477 | 10/20 | 0.68 |
| ▸ | F2 | P00734 | 9/20 | 0.68 |
| ▸ | PLG | P00747 | 5/20 | 0.68 |
| ▸ | PROC | P04070 | 1/20 | 0.49 |
| ▸ | FPR2 | P25090 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7115766 | 0.91 | F10 (0.56) | F10PRSS1F2PLGPROC | |
| SCHEMBL7126671 | 0.91 | F10 (0.70) | F10PRSS1F2PLGPROC | |
| SCHEMBL7116633 | 0.91 | F10 (0.56) | F10PRSS1F2PLGPROC | |
| SCHEMBL7126768 | 0.89 | F10 (0.54) | F10PRSS1F2PLGPROC | |
| SCHEMBL7119611 | 0.89 | F10 (0.54) | F10PRSS1F2PLGPROC | |
| SCHEMBL7121864 | 0.88 | F10 (0.53) | F10PRSS1F2PLGPROC | |
| SCHEMBL7123964 | 0.88 | F10 (0.53) | F10PRSS1F2PLGPROC | |
| SCHEMBL7112907 | 0.88 | F10 (0.53) | F10PRSS1F2PLGPROC | |
| SCHEMBL7112913 | 0.87 | F10 (0.52) | F10PRSS1F2PLGPROC | |
| SCHEMBL7114484 | 0.87 | F10 (0.51) | F10PRSS1F2PLGPROC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030187256-A1 | Benoxazinones/benzothiazinones as serine protease inhibitors | BERRYMAN KENT ALAN (US) | 2003-10-02 | — | — | US | claimed |
| EP-1068191-A1 | BENZOXAZINONES/BENZOTHIAZINONES AS SERINE PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2001-01-17 | — | — | EP | claimed |
| WO-1999050257-A1 | BENZOXAZINONES/BENZOTHIAZINONES AS SERINE PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-10-07 | — | — | WO | claimed |
| US-20030187256-A1 | Benoxazinones/benzothiazinones as serine protease inhibitors | BERRYMAN KENT ALAN (US) | 2003-10-02 | — | — | US | disclosed |
| US-6509335-B1 | This invention discloses benzoxazinone and benzothiazinone compounds which display inhibitory effects on serine proteases such as factor Xa, thrombin, and/or factor VIIa. The invention also discloses pharmaceutically acceptable salts of | WARNER-LAMBERT COMPANY | 2003-01-21 | — | — | US | disclosed |
| WO-2001026575-A9 | METHODS OF DIAGNOSING AND TREATING URINARY INCONTINENCE | UNIV LELAND STANFORD JUNIOR (US) | 2002-11-28 | — | — | WO | disclosed |
| US-6420119-B1 | DIAGNOSING UROGENITAL DISORDERS; OBTAIN TISSUE, MONITOR PROTEOLYSIS OF SUPPORT TISSUES, CLASSIFY UROGENITAL DISORDERS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JR. UNIVERSITY | 2002-07-16 | — | — | US | disclosed |
| WO-2001026575-A1 | METHODS OF DIAGNOSING AND TREATING URINARY INCONTINENCE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JR. UNIVERSITY (US) | 2001-04-19 | — | — | WO | disclosed |
| EP-1068191-A1 | BENZOXAZINONES/BENZOTHIAZINONES AS SERINE PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999050257-A1 | BENZOXAZINONES/BENZOTHIAZINONES AS SERINE PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187256-A1 | Benoxazinones/benzothiazinones as serine protease inhibitors | HABP2, SPINT2, SERPINB1 | F10 24/4885PRSS1 8/4885F2 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.